Amarna Therapeutics

Amarna Therapeutics B.V. is a pioneering biotech company based in The Netherlands, founded in 2008. The company's focus lies in the development of transformative, potentially curative gene therapies for rare and prevalent diseases. Amarna's proprietary production cell line, SuperVero™, enables the production of SV40-derived vectors suitable for therapeutic use, which is a breakthrough in gene therapy development. The company's gene therapy platform utilizes the genetically engineered SVec viral vector, allowing for the delivery of transgenes without eliciting immune responses. This feature is crucial in the development of safe, effective, and durable gene therapies for genetic disorders, autoimmune diseases, and chronic inflammation. With its head office in the Leiden Bio Science Park, the Netherlands, and a research subsidiary in Seville, Spain, Amarna has received a grant investment from Eurostars on 11 January 2022. Amarna's unique approach and promising technology make it a compelling player in the gene therapy space.